EichorEICHOR
Condition: Acute Lymphoblastic Leukemia All T Lymphoblastic Lymphoma Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Acute Lymphoblastic Leukemia All T Lymphoblastic Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05262673A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203CAR-T Immunotherapy Targeting CD19- ALL
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04016129Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Phase 1 · 16 location(s) · New York Medical College · NCT04972942Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leuke
Phase 1/Phase 2 · 2 location(s) · University of Chicago · NCT06207123Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
Phase 1 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07532525Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyc
Phase 1 · 2 location(s) · University of Kansas Medical Center · NCT03533816Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Phase 1 · 2 location(s) · OneChain Immunotherapeutics · NCT05679895Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05376111CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 · 2 location(s) · St. Jude Children's Research Hospital · NCT04318678U69-CART-Cells For R/R T-ALL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07350863CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT06847269Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461Bio-CAR-T BS Study
Phase N/A · 1 location(s) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di · NCT05366569Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Phase 1 · 3 location(s) · University College, London · NCT02443831Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 · 1 location(s) · yuejun Liu · NCT07012447CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 · 1 location(s) · Beijing Tongren Hospital · NCT06081478Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Phase 2 · 4 location(s) · St. Jude Children's Research Hospital · NCT06390319Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-R
Phase 1/Phase 2 · 1 location(s) · Liping Dou · NCT07575971Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 7 location(s) · British Columbia Cancer Agency · NCT06208735Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Maligna
Phase 1 · 1 location(s) · Nelson Hamerschlak · NCT05705570Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06633354
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.